Showing results (831-840 of 1,826) with videos related to

Sort By:
Pageof 183
Signal Transduction and Targeted Therapy|March 14, 2026
Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumorsYan-Ruide Li, Miao Li, Yuning Chen, et al.
Signal Transduction and Targeted Therapy|March 30, 2026
Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorderYaping Shao, Jing Wang, Yaping Liu, et al.
Signal Transduction and Targeted Therapy|February 22, 2026
Parathyroid hormone-related protein is a therapeutic target in idiopathic pulmonary fibrosisXue-Quan Fang, Suha Lim, Yoon-Mi Lee, et al.
Signal Transduction and Targeted Therapy|March 24, 2026
Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlatesJosephine Hallundbæk Ruders, Shamaila Munir Ahmad, Rasmus Erik Johansson Mortensen, et al.
Signal Transduction and Targeted Therapy|April 10, 2026
Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyondMads Hald Andersen
Signal Transduction and Targeted Therapy|March 27, 2026
PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failureWei Han, Yuheng Jiao, Wei Chen, et al.
Signal Transduction and Targeted Therapy|March 20, 2026
Fibrinogen-Bmal1 signaling as a therapeutic target to limit aortic dissection by preserving VSMC contractilityXiaohan Zhong, Dongjie Li, Yuanfei Zhao, et al.
Signal Transduction and Targeted Therapy|April 16, 2026
Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistanceZuming Yang, Shuaishuai Cao, Jiaen Zhang, et al.
Signal Transduction and Targeted Therapy|April 20, 2026
Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targetsPingjing Zheng, Wendi Yan, Yangnan Ding, et al.
Signal Transduction and Targeted Therapy|May 11, 2026
SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progressionOisun Jung, DeannaLee M Beauvais, Gavril L Ibaan, et al.
Pageof 183